Alzheimer’s Drug Faces Scrutiny Over Safety, Efficacy Concerns

Summary: The FDA-approved Alzheimer’s drug donanemab is under scrutiny due to concerns about its effectiveness and safety, according to an investigation. The study highlights multiple patient deaths during trials, design…

Alzheimer’s disease is partly genetic − studying the genes that delay decline in some may lead to treatments for all

Diseases that run in families usually have genetic causes. Some are genetic mutations that directly cause the disease if inherited. Others are risk genes that affect the body in a…